Unilever Australia Ltd v Revlon Australia Pty Ltd (No 7)

Link copied
Case Copied 23 min read

FEDERAL COURT OF AUSTRALIA

Unilever Australia Ltd v Revlon Australia Pty Ltd (No 7) [2015] FCA 137

Citation: Unilever Australia Ltd v Revlon Australia Pty Ltd (No 7) [2015] FCA 137
Parties: UNILEVER AUSTRALIA LTD ACN 004 050 828 v REVLON AUSTRALIA PTY LTD ACN 095 360 731
File number: NSD 508 of 2014
Judge: GLEESON J
Date of judgment: 3 March 2015
Catchwords: PRACTICE AND PROCEDURE – application to amend particulars – leave granted
Legislation: Federal Court Rules 2011 (Cth) r 16.51
Cases cited: AON Risk Services Australia Limited v Australian National University [2009] HCA 27; 239 CLR 175
Caason Investments Pty Ltd v Cao [2014] FCA 1410
Franklin v GHF Pty Ltd [2014] FCA 1414
Thomson v STX Pan Ocean Co Ltd [2012] FCAFC 15 Unilever v Revlon (No 6) [2014] FCA 1409
Date of hearing: 23 February 2015
Date of orders: 23 February 2015
3 March 2015
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 52
Counsel for the Applicant: Mr R Cobden SC with Mr N Furlan
Solicitor for the Applicant: Baker & McKenzie
Counsel for the Respondent: Mr M Hall SC with Dr B Kremer
Solicitor for the Respondent: King & Wood Mallesons

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 508 of 2014

BETWEEN:

UNILEVER AUSTRALIA LTD ACN 004 050 828
Applicant

AND:

REVLON AUSTRALIA PTY LTD ACN 095 360 731
Respondent

JUDGE:

GLEESON J

DATE OF ORDER:

23 FEBRUARY 2015

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.Leave be granted to the applicant to amend the particulars of the Further Amended Statement of Claim in the terms set out in annexure “A” to the affidavit of Andrew Salgo sworn 19 February 2015.

Note:    Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 508 of 2014

BETWEEN:

UNILEVER AUSTRALIA LTD ACN 004 050 828
Applicant

AND:

REVLON AUSTRALIA PTY LTD ACN 095 360 731
Respondent

JUDGE:

GLEESON J

DATE OF ORDER:

3 MARCH 2015

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.The applicant pay the costs thrown away by reason of the amendment.

2.The respondent pay the costs of the hearing of the application.

Note:    Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 508 of 2014

BETWEEN:

UNILEVER AUSTRALIA LTD ACN 004 050 828
Applicant

AND:

REVLON AUSTRALIA PTY LTD ACN 095 360 731
Respondent

JUDGE:

GLEESON J

DATE:

3 MARCH 2015

PLACE:

SYDNEY

REASONS FOR JUDGMENT

  1. On 23 February 2015, I made an order granting leave to the applicant (“Unilever”) to amend its particulars of paragraphs 26, 27, 41 and 46 of the Further Amended Statement of Claim (“statement of claim”) to include particulars to the effect that no hydrogen peroxide is present in the Mitchum Clinical products when applied to…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Unilever Australia Ltd v Revlon Australia Pty Ltd (No 7) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2015] FCA 137
Decision Date

CaseChat Overview and Summary

Unilever Australia Ltd sought leave to amend its particulars in the Federal Court of Australia in an action brought against Revlon Australia Pty Ltd concerning claims of misleading conduct in advertising Mitchum Clinical products. The core dispute was whether the Mitchum Clinical products contained hydrogen peroxide, and if so, in what quantity. The application for leave to amend the particulars was contentious, with Revlon opposing it on the grounds of potential prejudice and delay. The court needed to balance the considerations of fairness, the potential for prejudice to the respondent, and the overall pursuit of justice in the matter.

The legal issues before the court included whether the amendment would cause undue delay and prejudice to the respondent, and if the amendment was necessary to achieve justice between the parties. The court also considered the relevance of good faith on the part of the applicant and the potential impact of the amendment on the proceedings. The court examined the evidence presented by both parties and the extent to which the amendment was necessary to address the central issues of the case.

The court found that the amendment was not unduly prejudicial to Revlon and could be accommodated with reasonable time for Revlon to prepare further evidence. The court accepted that the presence or absence of hydrogen peroxide in Mitchum Clinical was a matter that Revlon should have been aware of and that the amendment did not stem from any lack of good faith. The court also noted that the amendment was not materially delayed and that the overall pursuit of justice would benefit from hearing the expert evidence. The court concluded that the potential prejudice could be sufficiently mitigated by allowing Revlon a reasonable opportunity to respond to the amended particulars.

The court granted leave to amend the particulars, ordered the applicant to pay the costs thrown away by the amendment, and directed the respondent to pay the costs of the hearing of the application. The detailed terms of the amendment were set out in the annexure to the affidavit of Andrew Salgo sworn on 19 February 2015.

Orders

Orders of the court

1. Leave be granted to the applicant to amend the particulars of the Further Amended Statement of Claim in the terms set out in annexure “A” to the affidavit of Andrew Salgo sworn 19 February 2015.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

1. The applicant pay the costs thrown away by reason of the amendment.

2. The respondent pay the costs of the hearing of the application.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Revlon identified the following matters as prejudice that it would suffer if the amendment was allowed:(1)Revlon will have had no opportunity to call evidence to prove the presence of hydrogen peroxide in Mitchum Clinical, such as commissioning its own equivalent of the Intertek test from an independent analytical laboratory (see paragraph 13 below);(2)Revlon has been denied the opportunity to test the evidence of Professor Thornthwaite, including questioning him on the reliability of the Intertek test results which are exhibited to Professor Thornthwaite’s own affidavit. When Professor Thornthwaite came and went, Intertek’s detection of hydrogen peroxide (though not the quantity) was common ground; and(3)Professor Perlmutter has not been given adequate time and opportunity to consider the new allegation that there is no hydrogen peroxide in Mitchum Clinical, in particular to deal with the Purported response to PP-9. Background to application Unilever commenced the proceeding on 23 May 2014. In support of its application for interlocutory relief, Unilever relied on a report by a testing laboratory Intertek Pharmaceutical Services (“Intertek report”) which had tested samples of the Mitchum Clinical soft solid antiperspirant deodorant to assess the level of hydrogen peroxide by weight in the product. The report indicated the presence of hydrogen peroxide at a level of 0.006%. According to Mr Salgo’s evidence, at the time of commencing the proceeding, Unilever considered that the result of the Intertek report was accurate. In an affidavit dated 28 May 2014, Dr Michael Traudt, Director of Sensory & Clinical Testing Center, Revlon Consumer Products Corporation, said:The form of hydrogen peroxide used in Mitchum Clinical is stabilised until it is activated by application to the axilla by a consumer. He also said:The methods used to ensure the stability of hydrogen peroxide in Mitchum Clinical are the subject of a confidential unpublished Patent Application…The unpublished Patent Application has not yet been published and is therefore confidential. I am aware from my extensive experience and knowledge in this field that the new Oxygen Odor Control Technology used in Mitchum Clinical is a “first” in the clinical anti-perspirant deodorant industry and a considerable revolutionary advance for clinical deodorants. Professor Thornthwaite, Unilever’s lead scientist at Unilever’s Research and Development Port Sunlight Laboratory in the United Kingdom swore his first affidavit on 27 June 2014. Professor Thornthwaite is an industrial chemist. His evidence addressed the potential efficacy of the hydrogen peroxide in the Mitchum Clinical products for delivery of benefits in malodour control. In that affidavit, he identified, as instructions or assumptions, a list of ingredients contained in the products including hydrogen peroxide. He also noted the results of the Intertek report. Professor Thornthwaite concluded, at paragraph 71 of his first affidavit, that any reaction between malodorous thiols with hydrogen peroxide present in Mitchum Clinical at around 0.006% or some multiples higher will not have any detectable impact on underarm malodour.

Evidence

Evidence Before The Court

In his affidavit, Mr Salgo deposed that the basis for the new contention, that hydrogen peroxide is not present in the Mitchum Clinical products at all, was not available to Unilever’s legal advisers prior to the tests and reports contained in and referred to in affidavits sworn by Professor Easton. Mr Salgo referred in particular to the views expressed by Professor Easton in his affidavit of 3 February 2015 and the Purported response to PP-9. Those views were based on:(1)Professor Easton’s consideration of the implications of tests reported in Dr Cai’s affidavit sworn 26 November 2014;(2)tests reported in Professor Easton’s affidavit of 3 February 2015, using encapsulated hydrogen peroxide; and(3)the tests and reasoning set out in the Purported response to PP-9.Revlon’s evidence In opposition to the application, Revlon read an affidavit of Katrina Rathie sworn on 22 February 2015. Revlon also relied on a bundle of documents that included an affidavit of Professor Perlmutter made on 22 February 2015. Attached to that affidavit is a document which appears to respond to the Purported response to PP-9 and which refers to two further experiments conducted by Professor Perlmutter. The bundle also contains an unsworn affidavit of Dr Cai which sets out evidence that Dr Cai would give in answer to the Purported response to PP-9. Ms Rathie gave evidence that Revlon has conducted its case on the basis that Unilever accepted that hydrogen peroxide was present in the Mitchum Clinical products. Her evidence was that, until the service of the Purported response to PP-9, and Unilever’s interlocutory application for leave to amend its particulars, Revlon took the view that it was not necessary to prove that Mitchum Clinical contained hydrogen peroxide because the issue between the parties was whether the amount admitted to be present was adequate. Revlon identified the following matters as prejudice that it would suffer if the amendment was allowed:(1)Revlon will have had no opportunity to call evidence to prove the presence of hydrogen peroxide in Mitchum Clinical, such as commissioning its own equivalent of the Intertek test from an independent analytical laboratory (see paragraph 13 below);(2)Revlon has been denied the opportunity to test the evidence of Professor Thornthwaite, including questioning him on the reliability of the Intertek test results which are exhibited to Professor Thornthwaite’s own affidavit. When Professor Thornthwaite came and went, Intertek’s detection of hydrogen peroxide (though not the quantity) was common ground; and(3)Professor Perlmutter has not been given adequate time and opportunity to consider the new allegation that there is no hydrogen peroxide in Mitchum Clinical, in particular to deal with the Purported response to PP-9. Background to application Unilever commenced the proceeding on 23 May 2014. In support of its application for interlocutory relief, Unilever relied on a report by a testing laboratory Intertek Pharmaceutical Services (“Intertek report”) which had tested samples of the Mitchum Clinical soft solid antiperspirant deodorant to assess the level of hydrogen peroxide by weight in the product. The report indicated the presence of hydrogen peroxide at a level of 0.006%. According to Mr Salgo’s evidence, at the time of commencing the proceeding, Unilever considered that the result of the Intertek report was accurate.

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established

The question of delay is a relevant factor to be taken into account: Caason Investments Pty Ltd v Cao [2014] FCA 1410 at [33]; Franklin v GHF Pty Ltd [2014] FCA 1414 at [21].Consideration The application was made at a late stage in the trial. Ten days of hearing had already been completed and the independent experts (Professor Perlmutter and Professor Easton) were expected to commence their concurrent evidence on the morning of Unilever’s application for leave to amend its particulars. One of the agreed issues for concurrent evidence was what is revealed by Dr Cai’s various experiments. In my view, the following matters warranted the grant of leave:(1)The composition of the Mitchum Clinical products and the presence or otherwise of the hydrogen peroxide at the time of application to the armpit is a matter that is, or should be, within the knowledge of Revlon; (2)Revlon should not be taken by surprise by the introduction of the proposed amended particulars because it has served evidence of several experiments intended to demonstrate the presence of hydrogen peroxide in the Mitchum Clinical products over time. Putting aside the Intertek analysis, it is obvious that if those experiments are contested (as they are) and do not demonstrate the presence of hydrogen peroxide in the products over time, there is an issue as to whether any hydrogen peroxide will be present in the products at all when it is applied to the armpit;(3)There is no suggestion of any lack of good faith on the part of Unilever in seeking to amend at this stage;(4)I accept Mr Salgo’s evidence recorded in paragraph 9 above and therefore am satisfied that there has been no material delay on the part of Unilever in seeking to amend. In particular, I do not accept that Professor Easton ought to have formed the opinion that he has now reached in September 2014: it was not unreasonable for him to have formed the more cautious conclusion that is set out in paragraph 28 above, in the absence of a consideration of Dr Cai’s further experimental evidence served in November 2014 and the patent application received in December 2014. It follows that I also do not accept the contention that Professor Easton was armed from July 2014 with all the information he needed to reach the conclusions he has arrived at in February 2015;(5)There is no currently no evidence that the Intertek analysis is conclusive as to the presence of hydrogen peroxide in the products. To the contrary, Dr Cai’s evidence raises a question about the reliability of the analysis (although he seems to suggest that it is reliable as to presence but not quantity);(6)Although the application is made late in the proceedings, in my view, the attainment of justice would not be served by refusing the application. If the amendment were refused, then the Court would determine the question whether Revlon has engaged in misleading conduct, or conduct likely to mislead, in its advertising to consumers on the basis of what would appear to be incomplete evidence about a matter that is, or should be, within Revlon’s knowledge; (7)The issue has been raised as the result of efforts by an independent expert to test the experiments performed by both Dr Cai and Professor Perlmutter (each without inviting Professor Easton to attend) to test the stability of the hydrogen peroxide included in the Mitchum products. In my view, the attainment of justice would not be served by declining to hear from Professor Easton as to matters that he has identified as of importance for the purpose of giving independent expert evidence. That view is fortified by the fact that his evidence is given in response to experiments put forward by Revlon which go to establishing that Mitchum will release hydrogen peroxide in the presence of sweat.(8)In my view, the prejudice identified on behalf of Revlon, arising from the proposed amendments, can be sufficiently prevented or ameliorated by permitting Revlon a reasonable time to adduce further evidence of the presence of hydrogen peroxide in the Mitchum Clinical products at the time of application to the underarm. That permission addresses the first item of prejudice identified by Ms Rathie. As to the second item, I am not satisfied that it is important for Professor Thornthwaite to be questioned on the reliability of the Intertek results. There is no evidence that he participated in or observed the Intertek analysis. As to the third item, before the application was argued I said that I would require evidence from Professor Perlmutter himself about what extra time, if any, he needed to address the Purported response to PP-9. No such evidence was tendered and, in fact, I received evidence that appears to address the Purported response to PP-9 and which does not identify any further work that he wishes to do to address the Purported response.